IBRX vs MSFT: Which Stock is Better?
Side-by-side comparison of Immunitybio Inc and Microsoft Corp in 2026
IBRX
Immunitybio Inc
$7.70
MSFT
Microsoft Corp
$422.50
Key Metrics Comparison
| Metric | IBRX | MSFT | Winner |
|---|---|---|---|
| Market Cap | $7.95B | N/A | IBRX |
| P/E Ratio | N/A | 26.31 | MSFT |
| EPS (TTM) | $N/A | $16.07 | MSFT |
| Revenue Growth | 4.1% | 0.2% | IBRX |
| Gross Margin | 99.3% | 68.6% | IBRX |
Analyze IBRX
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is IBRX or MSFT a better investment?
Comparing IBRX and MSFT: Immunitybio Inc has a market cap of $7.95B while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between IBRX and MSFT?
IBRX (Immunitybio Inc) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: IBRX or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: IBRX or MSFT?
IBRX has higher revenue growth at 4.1% vs 0.2% for MSFT.
Which company is more profitable: IBRX or MSFT?
Immunitybio Inc (IBRX) has higher gross margins at 99.3% compared to 68.6% for MSFT.
Which is the larger company: IBRX or MSFT?
Immunitybio Inc (IBRX) is larger with a market cap of $7.95B compared to N/A for MSFT.
Should I buy IBRX or MSFT in 2026?
Both IBRX and MSFT have investment merit. IBRX trades at $7.70 while MSFT trades at $422.50. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between IBRX and MSFT stock?
Key differences: Market Cap ($7.95B vs N/A), P/E Ratio (N/A vs 26.3x), Revenue Growth (4.1% vs 0.2%), Gross Margin (99.3% vs 68.6%).